A proteinogenic amino acid derivative resulting from the formal reaction of L-histidine at the amino group, carboxy group, or the imidazolyl moiety, or from the replacement of any hydrogen of L-histidine by a heteroatom.
ChEBI ID: 84076
| Member | Definition | Role |
|---|---|---|
| 1-methylhistidine | A L-histidine derivative in which the methyl group is at N(tele)-position. | N(tele)-methyl-L-histidine zwitterion; N(tele)-methyl-L-histidine |
| 3-methylhistidine | A L-histidine derivative that is L-histidine substituted by a methyl group at position 3 on the imidazole ring. | N(pros)-methyl-L-histidine zwitterion; N(pros)-methyl-L-histidine |
| 3-methylhistidine | N(pros)-methyl-L-histidine zwitterion; N(pros)-methyl-L-histidine | |
| ergothioneine | A L-histidine derivative that is N(alpha),N(alpha),N(alpha)-trimethyl-L-histidine in which the hydrogen at position 2 on the imdazole ring is replaced by a mercapto group. A naturally occurring metabolite of histidine synthesized by bacteria and fungi with antioxidant properties. It is found ubiquitously in plants and animals and is present in many human foodstuffs. | ergothioneine thione form; ergothioneine |
| ergothioneine | A L-histidine derivative that is N(alpha),N(alpha),N(alpha)-trimethyl-L-histidine in which the hydrogen at position 2 on the imdazole ring is replaced by a thioxo group. | ergothioneine thione form; ergothioneine |
| homocarnosine | A homocarnosine that has S configuration. | L-homocarnosine zwitterion; L-homocarnosine |
| L-histidine 2-naphthylamide | An L-histidine derivative that is the amide obtained by formal condensation of the carboxy group of L-histidine with the amino group of 2-naphthylamine. | L-histidine 2-naphthylamide |
| mln 4760 | A L-histidine derivative that is L-histidine in which a hydrogen of the primary amino group is substituted by a (1S)-1-carboxy-3-methylbutyl group and the ring NH group is substituted by a 3,5-dichlorobenzyl group. It is a potent and selective human angiotensin-converting enzyme 2 (ACE2) inhibitor (IC50 = 0.44 nM) which was in clinical development for the treatment of ulcerative colitis. | MLN-4760 |
| n-acetylhistidine | A histidine derivative that is L-histidine having an acetyl substituent on the alpha-nitrogen. | N-acetyl-L-histidine |
| ovothiol a | A L-histidine derivative that is L-histidine substituted at positions N3 and C5 on the imidazole ring by methyl and mercapto groups respectively. | ovothiol A zwitterion; ovothiol A |
| ovothiol c | A L-histidine derivative that is N,N-dimethyl-L-histidine substituted at positions N3 and C5 on the imidazole ring by methyl and mercapto groups respectively. | ovothiol C zwitterion; ovothiol C |
| ro 42-5892 | An L-histidine derivative that is L-histidine in which one of the amino hydrogens is replaced by a (2S)-2-[(2-methylpropane-2-sulfonyl)methyl]-3-phenylpropanoyl group and the carboxy group is replaced by a [(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino group. It is a renin inhibitor which was under development for the treatment of hypertension (now discontinued). | remikiren |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 529 (36.69) | 18.7374 |
| 1990's | 276 (19.14) | 18.2507 |
| 2000's | 204 (14.15) | 29.6817 |
| 2010's | 291 (20.18) | 24.3611 |
| 2020's | 142 (9.85) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 126 (8.08%) | 5.53% |
| Reviews | 91 (5.83%) | 6.00% |
| Case Studies | 7 (0.45%) | 4.05% |
| Observational | 1 (0.06%) | 0.25% |
| Other | 1,335 (85.58%) | 84.16% |